Trial · NCT03266588
Results by group144
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 144
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With SAEs and AEs Leading to Discontinuation During the Treatment Period | PRN (2-8) Group | Overall number of participants with at least 1 AE | 664 | Participants | |
| Number of Participants With SAEs and AEs Leading to Discontinuation During the Treatment Period | PRN (9-14) Group | Overall number of participants with at least 1 AE | 315 | Participants | |
| Number of Participants With SAEs and AEs Leading to Discontinuation During the Treatment Period | Scheduled EOD + PRN Group | Overall number of participants with at least 1 AE | 109 | Participants | |
| Number of Participants With SAEs and AEs Leading to Discontinuation During the Treatment Period | PRN (2-8) Group | AE ≥5%-Upper respiratory tract infection | 108 | Participants | |
| Number of Participants With SAEs and AEs Leading to Discontinuation During the Treatment Period | PRN (9-14) Group | AE ≥5%-Upper respiratory tract infection | 38 | Participants | |
| Number of Participants With SAEs and AEs Leading to Discontinuation During the Treatment Period | Scheduled EOD + PRN Group | AE ≥5%-Upper respiratory tract infection | 12 | Participants | |
| Number of Participants With SAEs and AEs Leading to Discontinuation During the Treatment Period | PRN (2-8) Group | Mild-Upper respiratory tract infection | 56 | Participants | |
| Number of Participants With SAEs and AEs Leading to Discontinuation During the Treatment Period | PRN (9-14) Group | Mild-Upper respiratory tract infection | 21 | Participants | |
| Number of Participants With SAEs and AEs Leading to Discontinuation During the Treatment Period | Scheduled EOD + PRN Group | Mild-Upper respiratory tract infection | 8 | Participants | |
| Number of Participants With SAEs and AEs Leading to Discontinuation During the Treatment Period | PRN (2-8) Group | Moderate-Upper respiratory tract infection | 51 | Participants | |
| Number of Participants With SAEs and AEs Leading to Discontinuation During the Treatment Period | PRN (9-14) Group | Moderate-Upper respiratory tract infection | 17 | Participants | |
| Number of Participants With SAEs and AEs Leading to Discontinuation During the Treatment Period | Scheduled EOD + PRN Group | Moderate-Upper respiratory tract infection | 4 | Participants | |
| Number of Participants With SAEs and AEs Leading to Discontinuation During the Treatment Period | PRN (2-8) Group | Severe-Upper respiratory tract infection | 1 | Participants | |
| Number of Participants With SAEs and AEs Leading to Discontinuation During the Treatment Period | PRN (9-14) Group | Severe-Upper respiratory tract infection | 0 | Participants | |
| Number of Participants With SAEs and AEs Leading to Discontinuation During the Treatment Period | Scheduled EOD + PRN Group | Severe-Upper respiratory tract infection | 0 | Participants | |
| Number of Participants With SAEs and AEs Leading to Discontinuation During the Treatment Period | PRN (2-8) Group | AE ≥5%-Nasopharyngitis | 72 | Participants | |
| Number of Participants With SAEs and AEs Leading to Discontinuation During the Treatment Period | PRN (9-14) Group | AE ≥5%-Nasopharyngitis | 41 | Participants | |
| Number of Participants With SAEs and AEs Leading to Discontinuation During the Treatment Period | Scheduled EOD + PRN Group | AE ≥5%-Nasopharyngitis | 9 | Participants | |
| Number of Participants With SAEs and AEs Leading to Discontinuation During the Treatment Period | PRN (2-8) Group | Mild-Nasopharyngitis | 53 | Participants | |
| Number of Participants With SAEs and AEs Leading to Discontinuation During the Treatment Period | PRN (9-14) Group | Mild-Nasopharyngitis | 28 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03266588/results